Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data

Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data

Abstract Background Secukinumab, a fully human immunoglobulin G1-kappa monoclonal antibody that directly inhibits interleukin (IL)-17A, has been shown to have robust efficacy in the treatment of moderate-to-severe psoriasis (PsO), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) demonstrat...

Full description

Bibliographic Details
Main Authors: A. Deodhar, P. J. Mease, I. B. McInnes, X. Baraliakos, K. Reich, A. Blauvelt, C. Leonardi, B. Porter, A. Das Gupta, A. Widmer, L. Pricop, T. Fox
Format: Article
Language:English
Published: BMC 2019-05-01
Series:Arthritis Research & Therapy
Subjects:
Spondyloarthritis
Safety
Biologics
Interleukin
TNF inhibitors
Online Access:http://link.springer.com/article/10.1186/s13075-019-1882-2

Internet

http://link.springer.com/article/10.1186/s13075-019-1882-2

Similar Items